{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T04:09:03Z","timestamp":1792382943733,"version":"4.4.0"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001412","name":"Council\u00a0of\u00a0Scientific and Industrial Research, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001412","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.bcp.2019.05.024","type":"journal-article","created":{"date-parts":[[2019,5,25]],"date-time":"2019-05-25T18:29:04Z","timestamp":1558808944000},"page":"185-191","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"special_numbering":"C","title":["Abaloparatide, the second generation osteoanabolic drug: Molecular mechanisms underlying its advantages over the first-in-class teriparatide"],"prefix":"10.1016","volume":"166","author":[{"given":"Sharmistha","family":"Bhattacharyya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhashis","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2473-0246","authenticated-orcid":false,"given":"Naibedya","family":"Chattopadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2019.05.024_b0005","unstructured":"S. Nussey, S. Whitehead, The parathyroid glands and vitamin D, in: Endocrinol. An Integr. Approach, BIOS Scientific Publishers, 2001. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK24\/ (accessed November 9, 2018)."},{"key":"10.1016\/j.bcp.2019.05.024_b0010","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.bbrc.2008.05.183","article-title":"PTHrP promotes chondrogenesis and suppresses hypertrophy from both bone marrow-derived and adipose tissue-derived MSCs","volume":"373","author":"Kim","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bcp.2019.05.024_b0015","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1089\/scd.2014.0101","article-title":"Intermittent PTHrP(1\u201334) exposure augments chondrogenesis and reduces hypertrophy of mesenchymal stromal cells","volume":"23","author":"Fischer","year":"2014","journal-title":"Stem Cells Dev."},{"key":"10.1016\/j.bcp.2019.05.024_b0020","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1002\/jbmr.1617","article-title":"Twenty-five years of PTHrP progress: From cancer hormone to multifunctional cytokine","volume":"27","author":"McCauley","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bcp.2019.05.024_b0025","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1093\/clinchem\/38.11.2171","article-title":"Parathyroid Hormone-Related Protein: Structure, Function, and Measurement","volume":"38","author":"Burtis","year":"1992","journal-title":"Clin. Chem."},{"key":"10.1016\/j.bcp.2019.05.024_b0030","doi-asserted-by":"crossref","unstructured":"T.J. Martin, Parathyroid hormone-related protein, its regulation of cartilage and bone development, and role in treating bone diseases, (2016). doi: 10.1152\/physrev.00031.2015.","DOI":"10.1152\/physrev.00031.2015"},{"key":"10.1016\/j.bcp.2019.05.024_b0035","doi-asserted-by":"crossref","first-page":"16525","DOI":"10.1073\/pnas.0808750105","article-title":"Prolonged signaling at the parathyroid hormone receptor by peptide ligands targeted to a specific receptor conformation","volume":"43105","author":"Okazaki","year":"2008","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bcp.2019.05.024_b0040","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1210\/me.2007-0274","article-title":"Altered selectivity of parathyroid hormone (PTH) and PTH-related protein (PTHrP) for distinct conformations of the PTH\/PTHrP receptor","volume":"22","author":"Dean","year":"2008","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.bcp.2019.05.024_b0045","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1073\/pnas.86.7.2408","article-title":"Isolation and characterization of the human parathyroid hormone-like peptide gene (parathyroid hormone\/alternative splicing\/chromosome 12)","volume":"86","author":"Mangin","year":"1989","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.bcp.2019.05.024_b0050","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.cellsig.2009.02.012","article-title":"PTH and PTHrP signaling in osteoblasts","volume":"21","author":"Datta","year":"2009","journal-title":"Cell. Signal."},{"key":"10.1016\/j.bcp.2019.05.024_b0055","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/1097-0282(200011)54:6<429::AID-BIP70>3.0.CO;2-W","article-title":"Conformational studies of parathyroid hormone (PTH)\/PTH-related protein (PTHrp) chimeric peptides","volume":"54","author":"Schievano","year":"2000","journal-title":"Biopolymers"},{"key":"10.1016\/j.bcp.2019.05.024_b0060","doi-asserted-by":"crossref","first-page":"28650","DOI":"10.1074\/jbc.M100717200","article-title":"multiple sites of contact between the carboxyl-terminal binding domain of PTHrP-(1\u201336) analogs and the amino-terminal extracellular domain of the PTH\/PTHrP receptor identified by photoaffinity cross-linking*","volume":"276","author":"Gensure","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2019.05.024_b0065","doi-asserted-by":"crossref","first-page":"14931","DOI":"10.1074\/jbc.271.25.14931","article-title":"Structurally diverse N-terminal peptides of parathyroid hormone (PTH) and PTH-related peptide (PTHRP) inhibit the Na+\/H+ exchanger NHE3 isoform by binding to the PTH\/PTHRP receptor type I and activating distinct signaling pathways","volume":"271","author":"Azarani","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2019.05.024_b0070","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0014-5793(98)01658-5","article-title":"The structure of human parathyroid hormone-related protein(1\u201334) in near-physiological solution","volume":"444","author":"Weidler","year":"1999","journal-title":"FEBS Lett."},{"key":"10.1016\/j.bcp.2019.05.024_b0075","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/nrendo.2015.139","article-title":"PTH receptor-1 signalling-mechanistic insights and therapeutic prospects","volume":"11","author":"Cheloha","year":"2015","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.bcp.2019.05.024_b0080","doi-asserted-by":"crossref","first-page":"28382","DOI":"10.1074\/jbc.M109.022905","article-title":"Structural basis for parathyroid hormone-related protein binding to the parathyroid hormone receptor and design of conformation-selective peptides","volume":"284","author":"Pioszak","year":"2009","journal-title":"J. Biol. Chem."},{"issue":"43","key":"10.1016\/j.bcp.2019.05.024_b0085","doi-asserted-by":"crossref","first-page":"32485","DOI":"10.1074\/jbc.M606179200","article-title":"Role of amino acid side chains in the (17\u201331) domain of parathyroid hormone in binding to the PTH receptor","volume":"281","author":"Dean","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2019.05.024_b0090","doi-asserted-by":"crossref","first-page":"19456","DOI":"10.1074\/jbc.M001596200","article-title":"Autoactivation of type-1 parathyroid hormone receptors containing a tethered ligand","volume":"275","author":"Shimizu","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2019.05.024_b0095","doi-asserted-by":"crossref","first-page":"21836","DOI":"10.1074\/jbc.M909861199","article-title":"Minimization of parathyroid hormone. Novel amino-terminal parathyroid hormone fragments with enhanced potency in activating the type-1 parathyroid hormone receptor","volume":"275","author":"Shimizu","year":"2000","journal-title":"J. Biol. Chem."},{"issue":"44","key":"10.1016\/j.bcp.2019.05.024_b0100","doi-asserted-by":"crossref","first-page":"13224","DOI":"10.1021\/bi026162k","article-title":"Residue 19 of the parathyroid hormone (PTH) modulates ligand interaction with the juxtamembrane region of the PTH-1 receptor\u2020","volume":"41","author":"Shimizu","year":"2002","journal-title":"Biochemistry"},{"key":"10.1016\/j.bcp.2019.05.024_b0105","doi-asserted-by":"crossref","first-page":"49003","DOI":"10.1074\/jbc.M106827200","article-title":"Parathyroid Hormone (PTH)-(1\u201314) and -(1\u201311) analogs conformationally constrained by alpha-aminoisobutyric acid mediate full agonist responses via the juxtamembrane region of the PTH-1 receptor*","volume":"276","author":"Shimizu","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2019.05.024_b0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00018-010-0465-9","article-title":"Molecular basis of parathyroid hormone receptor signaling and trafficking: a family B GPCR paradigm","volume":"68","author":"Vilardaga","year":"2011","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.bcp.2019.05.024_b0115","doi-asserted-by":"crossref","first-page":"38524","DOI":"10.1074\/jbc.M202544200","article-title":"Selective ligand-induced stabilization of active and desensitized parathyroid hormone type 1 receptor conformations","volume":"277","author":"Bisello","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2019.05.024_b0120","doi-asserted-by":"crossref","first-page":"10856","DOI":"10.1074\/jbc.M513380200","article-title":"Distinct beta-arrestin- and G protein-dependent pathways for parathyroid hormone receptor-stimulated ERK1\/2 activation","volume":"281","author":"Gesty-Palmer","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2019.05.024_b0125","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.bbrc.2004.11.069","article-title":"Parathyroid hormone and parathyroid hormone-related peptide, and their receptors","volume":"328","author":"Gensure","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bcp.2019.05.024_b0130","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1124\/jpet.112.199752","article-title":"Parathyroid hormone (PTH) and PTH-related peptide domains contributing to activation of different PTH receptor-mediated signaling pathways","volume":"345","author":"Cupp","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2019.05.024_b0135","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1210\/me.2005-0349","article-title":"Mechanisms of ligand binding to the parathyroid hormone (PTH)\/PTH-related protein receptor: selectivity of a modified PTH(1\u201315) radioligand for GalphaS-coupled receptor conformations","volume":"20","author":"Dean","year":"2006","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.bcp.2019.05.024_b0140","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/nchembio.206","article-title":"Sustained cyclic AMP production by parathyroid hormone receptor endocytosis","volume":"5","author":"Ferrandon","year":"2009","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bcp.2019.05.024_b0145","doi-asserted-by":"crossref","first-page":"5864","DOI":"10.1073\/pnas.1301674110","article-title":"Critical role of parathyroid hormone (PTH) receptor-1 phosphorylation in regulating acute responses to PTH","volume":"110","author":"Maeda","year":"2013","journal-title":"PNAS"},{"key":"10.1016\/j.bcp.2019.05.024_b0150","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/nchembio.545","article-title":"Retromer terminates the generation of cAMP by internalized PTH-receptors HHS Public Access Author manuscript","volume":"7","author":"Feinstein","year":"2011","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bcp.2019.05.024_b0155","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nrm2748","article-title":"Endocytosis and signalling: intertwining molecular networks","volume":"10","author":"Sorkin","year":"2009","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bcp.2019.05.024_b0160","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1093\/emboj\/18.4.893","article-title":"The MAP kinase ERK2 inhibits the cyclic AMP-specific phosphodiesterase HSPDE4D3 by phosphorylating it at Ser579","volume":"18","author":"Hoffmann","year":"1999","journal-title":"EMBO J."},{"key":"10.1016\/j.bcp.2019.05.024_b0165","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1073\/pnas.1205756110","article-title":"Noncanonical GPCR signaling arising from a PTH receptor-arrestin-G\u03b2\u03b3 complex","volume":"110","author":"Wehbi","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.bcp.2019.05.024_b0170","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1210\/en.2015-1726","article-title":"Binding selectivity of abaloparatide for PTH-type-1-receptor conformations and effects on downstream signaling","volume":"157","author":"Hattersley","year":"2016","journal-title":"Endocrinology"},{"key":"10.1016\/j.bcp.2019.05.024_b0175","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.bone.2016.11.027","article-title":"One year of abaloparatide, a selective peptide activator of the PTH1 receptor, increased bone mass and strength in ovariectomized rats","volume":"95","author":"Varela","year":"2017","journal-title":"Bone"},{"key":"10.1016\/j.bcp.2019.05.024_b0180","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1517\/13543784.2010.501077","article-title":"Investigational anabolic therapies for osteoporosis","volume":"19","author":"Trivedi","year":"2010","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.bcp.2019.05.024_b0185","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1210\/jc.2014-3718","article-title":"Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis","volume":"100","author":"Leder","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bcp.2019.05.024_b0190","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00198-017-4304-9","article-title":"Abaloparatide-SC improves trabecular microarchitecture as assessed by trabecular bone score (TBS): a 24-week randomized clinical trial","volume":"29","author":"Bilezikian","year":"2018","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bcp.2019.05.024_b0195","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis","volume":"316","author":"Miller","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.bcp.2019.05.024_b0200","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/jbmr.3163","article-title":"The effect of abaloparatide-SC on fracture risk is independent of baseline FRAX fracture probability: a post hoc analysis of the ACTIVE study","volume":"32","author":"McCloskey","year":"2017","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bcp.2019.05.024_b0205","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/GME.0000000000001080","article-title":"Effects of abaloparatide on bone mineral density and risk of fracture in postmenopausal women aged 80 years or older with osteoporosis","volume":"25","author":"McClung","year":"2018","journal-title":"Menopause"},{"key":"10.1016\/j.bcp.2019.05.024_b0210","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1177\/1060028017748649","article-title":"Abaloparatide: review of a next-generation parathyroid hormone agonist","volume":"52","author":"Boyce","year":"2018","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.bcp.2019.05.024_b0215","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/jbmr.2991","article-title":"Effects of abaloparatide-SC on fractures and bone mineral density in subgroups of postmenopausal women with osteoporosis and varying baseline risk factors","volume":"32","author":"Cosman","year":"2017","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bcp.2019.05.024_b0220","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.bone.2018.10.015","article-title":"Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: results from the ACTIVE phase 3 trial","volume":"120","author":"Miller","year":"2019","journal-title":"Bone"},{"key":"10.1016\/j.bcp.2019.05.024_b0225","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/jbmr.3042","article-title":"Abaloparatide is an anabolic, but does it spare resorption?","volume":"32","author":"Martin","year":"2017","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bcp.2019.05.024_b0230","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1210\/jc.2018-00163","article-title":"ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis","volume":"103","author":"Bone","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bcp.2019.05.024_b0235","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa050336","article-title":"One year of alendronate after one year of parathyroid hormone (1\u201384) for osteoporosis","volume":"353","author":"Black","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2019.05.024_b0240","first-page":"2129","article-title":"Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate*","volume":"85","author":"Rittmaster","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bcp.2019.05.024_b0245","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1007\/s00198-004-1636-z","article-title":"The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]","volume":"15","author":"Kurland","year":"2004","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bcp.2019.05.024_b0250","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00774-015-0731-x","article-title":"The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis","volume":"35","author":"Ebina","year":"2017","journal-title":"J. Bone Miner. Metab."},{"key":"10.1016\/j.bcp.2019.05.024_b0255","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1002\/jbmr.1978","article-title":"A comparison of parathyroid hormone-related protein (1\u201336) and parathyroid hormone (1\u201334) on markers of bone turnover and bone density in postmenopausal women: the PrOP study","volume":"28","author":"Horwitz","year":"2013","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bcp.2019.05.024_b0260","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s00198-017-4323-6","article-title":"Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption","volume":"29","author":"Doyle","year":"2018","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bcp.2019.05.024_b0265","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1002\/jbmr.1784","article-title":"Differing effects of PTH 1\u201334, PTH 1\u201384, and zoledronic acid on bone microarchitecture and estimated strength in postmenopausal women with osteoporosis: An 18-month open-labeled observational study using HR-pQCT","author":"Hansen","year":"2013","journal-title":"J. Bone Miner. Res. 28"},{"key":"10.1016\/j.bcp.2019.05.024_b0270","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1007\/s002230010091","article-title":"Changes in geometry and cortical porosity in adult, ovary-intact rabbits after 5 months treatment with LY333334 (hPTH 1\u201334)","volume":"66","author":"Hirano","year":"2000","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bcp.2019.05.024_b0275","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1359\/jbmr.2001.16.1.157","article-title":"Intermittently administered human parathyroid hormone(1\u201334) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys","volume":"16","author":"Burr","year":"2001","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bcp.2019.05.024_b0280","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0175329","article-title":"Acute development of cortical porosity and endosteal na\u00efve bone formation from the daily but not weekly short-term administration of PTH in rabbit","volume":"12","author":"Yamane","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2019.05.024_b0285","article-title":"Administration frequency as well as dosage of PTH are associated with development of cortical porosity in ovariectomized rats","volume":"5","author":"Takakura","year":"2017","journal-title":"Nat. Publ. Gr."},{"key":"10.1016\/j.bcp.2019.05.024_b0290","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.bone.2016.11.004","article-title":"Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: the ACTIVE phase 3 trial","volume":"97","author":"Moreira","year":"2017","journal-title":"Bone"},{"key":"10.1016\/j.bcp.2019.05.024_b0295","first-page":"477","article-title":"Comparison of the effects of intermittent and continuous administration of human parathyroid hormone(1\u201334) on rat bone","volume":"16","author":"Uzawa","year":"1995","journal-title":"Bone"},{"key":"10.1016\/j.bcp.2019.05.024_b0300","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1210\/jc.2002-021122","article-title":"Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis","volume":"88","author":"Horwitz","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bcp.2019.05.024_b0305","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/jcb.20506","article-title":"Effects of parathyroid hormone on Wnt signaling pathway in bone","volume":"95","author":"Kulkarni","year":"2005","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.bcp.2019.05.024_b0310","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1210\/endo-124-3-1247","article-title":"Parathyroid hormone enhances the transcript and polypeptide levels of insulin-like growth factor I in osteoblast-enriched cultures from fetal rat bone*","volume":"124","author":"McCarthy","year":"1989","journal-title":"Endocrinology"},{"key":"10.1016\/j.bcp.2019.05.024_b0315","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.bone.2005.03.018","article-title":"SOST is a target gene for PTH in bone","volume":"37","author":"Keller","year":"2005","journal-title":"Bone"},{"key":"10.1016\/j.bcp.2019.05.024_b0320","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.cmet.2009.12.007","article-title":"Suppression of Wnt signaling by Dkk1 attenuates PTH-mediated stromal cell response and new bone formation","volume":"11","author":"Guo","year":"2010","journal-title":"Cell Metab."},{"key":"10.1016\/j.bcp.2019.05.024_b0325","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1210\/endo-118-2-824","article-title":"Osteoblastic cells mediate osteoclastic responsiveness to parathyroid hormone","volume":"118","author":"McSheehy","year":"1986","journal-title":"Endocrinology"},{"key":"10.1016\/j.bcp.2019.05.024_b0330","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1210\/jc.2009-0154","article-title":"Effects of teriparatide retreatment in osteoporotic men and women","volume":"94","author":"Finkelstein","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bcp.2019.05.024_b0335","doi-asserted-by":"crossref","first-page":"48868","DOI":"10.1074\/jbc.M208494200","article-title":"Parathyroid hormone stimulates receptor activator of NFkappa B ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein","volume":"277","author":"Fu","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2019.05.024_b0340","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.bone.2007.03.017","article-title":"Molecular and cellular mechanisms of the anabolic effect of intermittent PTH","volume":"40","author":"Jilka","year":"2007","journal-title":"Bone"},{"key":"10.1016\/j.bcp.2019.05.024_b0345","first-page":"1","article-title":"Abaloparatide exerts bone anabolic effects with less stimulation of bone resorption-related factors: a comparison with teriparatide","author":"Makino","year":"2018","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bcp.2019.05.024_b0350","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.clinthera.2017.05.348","article-title":"A model for assessing the clinical and economic benefits of bone-forming agents for reducing fractures in postmenopausal women at high, near-term risk of osteoporotic fracture","volume":"39","author":"O\u2019Hanlon","year":"2017","journal-title":"Clin. Ther."},{"key":"10.1016\/j.bcp.2019.05.024_b0355","first-page":"1","article-title":"Cost-effectiveness of sequential treatment with abaloparatide vs. teriparatide for United States women at increased risk of fracture","author":"Hiligsmann","year":"2019","journal-title":"Semin. Arthritis Rheum."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295219302126?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295219302126?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:04:44Z","timestamp":1757768684000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295219302126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":71,"alternative-id":["S0006295219302126"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2019.05.024","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Abaloparatide, the second generation osteoanabolic drug: Molecular mechanisms underlying its advantages over the first-in-class teriparatide","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2019.05.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}